迪安诊断1月30日获融资买入1.12亿元，融资余额8.30亿元

Core Viewpoint - Dian Diagnostics experienced a decline of 4.63% in stock price on January 30, with a trading volume of 1.18 billion yuan, indicating potential market concerns regarding its financial performance and investor sentiment [1]. Financing Summary - On January 30, Dian Diagnostics had a financing buy amount of 112 million yuan and a financing repayment of 153 million yuan, resulting in a net financing outflow of 41.13 million yuan [1]. - The total financing and securities balance for Dian Diagnostics reached 832 million yuan, with the financing balance accounting for 5.56% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 13,200 shares were repaid while 10,100 shares were sold, with a selling amount of 241,300 yuan, and the remaining securities lending balance was 76,800 shares, valued at 1.83 million yuan, also above the 60th percentile of the past year [1]. Financial Performance Summary - As of September 30, the number of shareholders for Dian Diagnostics was 45,700, a decrease of 5.45% from the previous period, while the average circulating shares per person increased by 5.76% to 10,974 shares [2]. - For the period from January to September 2025, Dian Diagnostics reported a revenue of 7.566 billion yuan, a year-on-year decrease of 18.28%, and a net profit attributable to shareholders of 56.70 million yuan, down 56.67% year-on-year [2]. Dividend and Shareholding Summary - Since its A-share listing, Dian Diagnostics has distributed a total of 1.099 billion yuan in dividends, with 712 million yuan distributed over the past three years [3]. - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited as the third-largest shareholder with 10.5635 million shares, a decrease of 4.235 million shares from the previous period [3]. - The Southern CSI 1000 ETF ranked as the seventh-largest shareholder with 4.5688 million shares, down by 40,900 shares, while the Medical Device ETF entered as the tenth-largest shareholder with 3.0875 million shares [3].